Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

Journal of Clinical Pharmacology- United States

doi 10.1002/jcph.1312

Full Text

Abstract

Available in

Categories

Pharmacology

Date

Authors

Publisher

Wiley

Related search

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

Clinical Pharmacokinetics
Pharmacology
2013English

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora a Kinase Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2012English

Tyrosine Kinase Inhibitor and Target Therapy

2013English

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase

English

Evaluation of a Tyrosine Kinase Peptide Microarray for Tyrosine Kinase Inhibitor Therapy Selection in Cancer

Experimental & Molecular Medicine
2016English

Development of a Pharmacodynamic Assay Based on PLCγ2 Phosphorylation for Quantifying Spleen Tyrosine Kinase (SYK)–Bruton’s Tyrosine Kinase (BTK) Signaling

Journal of Biomolecular Screening
Molecular MedicinePharmacologyBiochemistryAnalytical ChemistryBiotechnologyDrug Discovery
2013English

Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

Inhibition of IgE-mediated Secretion From Human Basophils With a Highly Selective Bruton's Tyrosine Kinase, Btk, Inhibitor

International Immunopharmacology
AllergyImmunologyPharmacology
2011English

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

AAPS Journal
Pharmaceutical Science
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy